Neonatal Meningitis

Distinct Aetiology (vs general pyogenic meningitis)

Dominant: Group B Streptococcus (S. agalactiae) + E. coli (esp. K1 capsular antigen strains — specific neuroinvasive association). Third: Listeria monocytogenes — WHY ampicillin added to empirical neonatal/elderly/immunocompromised regimens (cross-ref Pyogenic Meningitis topic).

Transmission/Risk Factors

Vertical transmission: maternal genital tract, intrapartum (birth canal) or ascending pre-delivery. GBS = common ASYMPTOMATIC maternal genital/rectal colonizer (cf. Normal Microbial Flora — colonizer→pathogen in vulnerable host) → basis for maternal GBS SCREENING + INTRAPARTUM ANTIBIOTIC PROPHYLAXIS (effective standard practice). Risk factors: prematurity, low birth weight, prolonged rupture of membranes, maternal intrapartum fever.

Clinical — NONSPECIFIC (key testable point)

NOT classic triad. Poor feeding, lethargy, temp INSTABILITY (hypothermia as often as fever), irritability, vomiting. Kernig’s/Brudzinski’s unreliable/absent in neonates. Bulging fontanelle: more specific sign (open sutures) but not universal. → LOW THRESHOLD for LP in septic-appearing neonate — exam alone insufficient.

Diagnosis

CSF: same general bacterial pattern (↑pressure, neutrophilic, low glucose, ↑protein) BUT age-appropriate neonatal reference ranges differ from adult (see CSF Examination in Meningitis). Blood culture: important complementary test — neonatal meningitis often co-occurs with sepsis/bacteremia.

Treatment/Prevention

Empirical: Ampicillin (GBS + Listeria) + 3rd-gen cephalosporin OR aminoglycoside (E. coli/gram-negative). Distinct composition from adult regimen, same “cover age-appropriate pathogens without delay” principle. Prevention: Universal maternal GBS screening (vaginorectal swab, late 3rd trimester) + intrapartum antibiotic prophylaxis (penicillin/ampicillin) for colonized/risk-factor mothers — proven effective, reduces early-onset GBS disease.

A Genuinely Distinct Aetiological Profile

Neonatal meningitis is deliberately treated as its own topic, separate from the general pyogenic meningitis discussion, because the causative organisms in this specific age group are genuinely, substantially different from those dominating meningitis in older children and adults (see Pyogenic (Bacterial) Meningitis) — a real, testable point of contrast rather than a simple age-extension of the same disease. The two dominant neonatal pathogens are Group B Streptococcus (Streptococcus agalactiae) and Escherichia coli (particularly strains bearing the K1 capsular antigen, genuinely notable for its specific association with neonatal invasive disease and meningitis), with Listeria monocytogenes as a genuinely important, if less common, third organism — this Listeria involvement is precisely why ampicillin is specifically added to empirical antibiotic regimens in the neonatal age group, as already flagged under the general pyogenic meningitis topic.

Transmission and Risk Factors

Infection is acquired predominantly via vertical transmission from the maternal genital tract, either during passage through the birth canal (intrapartum) or, less commonly, by ascending infection before delivery — Group B Streptococcus, in particular, is a genuinely common asymptomatic maternal genital/rectal colonizer (a real point of overlap with the general concept of normal/colonizing flora becoming pathogenic in a vulnerable host, covered under Normal Microbial Flora), which is precisely why maternal GBS screening late in pregnancy and intrapartum antibiotic prophylaxis for colonized mothers has become a standard, genuinely effective preventive obstetric practice. Prematurity, low birth weight, prolonged rupture of membranes, and maternal intrapartum fever are recognized risk factors that increase neonatal susceptibility, reflecting both increased organism exposure and the neonate’s genuinely immature immune defences.

Clinical Manifestations — A Genuinely Nonspecific Presentation

A specifically important, testable clinical point: neonatal meningitis frequently presents with nonspecific signs — poor feeding, lethargy, temperature instability (hypothermia as often as fever), irritability, and vomiting — rather than the classic fever/neck stiffness/altered mental status triad seen in older patients, since neonates genuinely cannot mount or display the same meningeal signs (Kernig’s/Brudzinski’s are typically unreliable or absent in this age group). A bulging fontanelle is a more specific, though not universally present, sign in this age group given the still-open cranial sutures, and its presence should raise strong suspicion. This nonspecific presentation genuinely demands a low threshold for lumbar puncture in any neonate with sepsis-like features, since clinical examination alone is frequently insufficient to exclude meningitis with confidence.

Laboratory Diagnosis

CSF analysis follows the same general bacterial-meningitis pattern described under Pyogenic (Bacterial) Meningitis (elevated pressure, neutrophil-predominant pleocytosis, low glucose, elevated protein), though genuinely worth noting that normal neonatal CSF reference ranges differ somewhat from those in older children/adults (see CSF Examination in Meningitis for comparative parameters), meaning interpretation requires age-appropriate reference values rather than adult norms. Blood culture is genuinely important as a complementary test, since neonatal meningitis frequently occurs in the context of concurrent bacteraemia/sepsis, and a positive blood culture can support the diagnosis even where CSF sampling is technically difficult or delayed.

Treatment and Prevention

Empirical treatment specifically covers the neonatal-specific organism profile: ampicillin (for GBS and Listeria coverage) combined with a third-generation cephalosporin or an aminoglycoside (for E. coli and other gram-negative coverage), genuinely distinct in composition from the adult empirical regimen even though the underlying “cover the age-appropriate major pathogens empirically without delay” principle is shared. Prevention centres on universal maternal GBS screening (typically by vaginorectal swab culture late in the third trimester) and intrapartum antibiotic prophylaxis (typically penicillin or ampicillin) for identified GBS-colonized mothers or those with other recognized risk factors — a genuinely effective, widely implemented obstetric intervention that has measurably reduced early-onset neonatal GBS disease incidence where consistently applied.